Jenny Löfgren
ID: UNCST-2024-R005428
|
Outcomes of paediatric inguinal hernia repair performed by surgeons versus medical officers
REFNo: HS4508ES
Calculate and compare costs and cost-effectiveness between the two groups. ,Compare patient related outcomes between the group that has been operated on by medical officers versus those who were operated by general surgeons. ,The general objective of the proposed study is to investigate the possibility of task sharing between general surgeons and medical officers in inguinal hernia repair in children in Uganda. ,
|
Soroti,
Mubende,
Iganga,
|
Sweden |
2024-07-23 15:30:50 |
2027-07-23 |
341 |
Children, both girls and boys, 1-12 years old. |
Swedish Research Council |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Jerome Kabakyenga Kahuma
ID: UNCST-2021-R013729
|
The A-Lite vein locator: “a non-invasive assistive medical device designed to improve vein visibility among patients requiring intravenous therapy.â€
REFNo: HS1547ES
Main Objective
1. To assess the efficacy, safety and impact of using an assistive medical device to aid vein visibility among patients requiring intravenous therapy.
Specific Objectives
1. To assess the safety and efficacy of the A-Lite vein locator among 10 adults in Uganda.
2. To investigate non-inferiority by assessing the performance of the A-Lite vein locator with respect to the existing standard of care among 48 adolescents in Uganda.
3. To determine the effectiveness of using the A-Lite vein locator for improving vein visibility among 156 children requiring intravenous cannulation in Uganda.
|
Kalungu, Bugonzi
Lira, Junior Quarters
Mbarara, Rwebishekye
Isingiro, Kashojwa
|
Uganda |
2021-11-19 |
2024-11-19 |
214 |
Ages eligible for the study: 1 up to 30 years
Sexes eligible for the study: All
|
International Development Research Centre (IDRC) – Canada and the Government of Uganda |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jonathan Kayondo
ID: UNCST-2021-R008325
|
Multi-Centre, Prospective, Evaluation for Matrix equivalence of capillary whole blood finger-stick and fresh and frozen venous whole blood with the NxTekâ„¢ Malaria Pf Plus Rapid Test Device and NxTekâ„¢ Malaria Pf/Pv Plus Rapid Test Device for the Detection of Plasmodium Infections in Patients with Symptoms Suggestive of Malaria within the Lab and its intended use environment for CE IVDR.
REFNo: HS1587ES
This trial is part of the R&D Verification and Validation studies, to provide clinical matrix equivalence evaluation to support the conformity assessment procedure for the use of fingerstick and venous whole blood samples with Abbott’s NxTek™ Malaria Pf Plus and NxTek™ Malaria Pf/Pv Plus Rapid Test Devices, as performed by professional users, in accordance with WHO PQ TSS-3, WHO PQ Dossier, EU 2017/7461.
Primary Objective: Matrix Equivalence
To assess the matrix equivalence of:
a. Fresh CWBFS and Fresh VWB
b. Frozen VWB and Fresh VWB
when used with the NxTekâ„¢ Malaria Pf/Pv Plus and NxTekâ„¢ Malaria Pf Plus by laboratory professionals (from hereon referred to as Lab operators) in a laboratory environment to support CE IVDR certification.
The test results of the NxTekâ„¢ Malaria Pf Plus and NxTekâ„¢ Malaria Pf/Pv Plus Rapid Test using a VWB sample, will be evaluated against the NxTekâ„¢ Malaria Pf Plus and NxTekâ„¢ Malaria Pf/Pv Plus Rapid Test using CWBFS sample from the same participant. In summary: Fresh CWBFS vs. Fresh VWB*. Likewise, the test results of the NxTekâ„¢ Malaria Pf Plus and NxTekâ„¢ Malaria Pf/Pv Plus Rapid Test using VWB samples that have been exposed to 1x Freeze/Thaw cycle will be evaluated against the NxTekâ„¢ Malaria Pf Plus and NxTekâ„¢ Malaria Pf/Pv Plus Rapid Test using fresh VWB samples from the same participant. In summary: Frozen VWB vs. Fresh VWB*
*indicates: Where Fresh VWB will be the comparator sample type.
The data obtained will be used in the application for CE IVDR certification and WHO PQ. Paired CWBFS and VWB samples will be taken from the same individuals for testing on both NxTekâ„¢ Malaria Pf/Pv Plus and NxTekâ„¢ Malaria Pf Plus RDTs.
Secondary Objective: Intended Users within the Intended Use Environment
Malaria RDTs are used outside of the laboratory for near patient testing (NPT)* by non laboratory healthcare workers with limited training. Thus the secondary objective of this study is to assess the perfromance of the NxTekâ„¢ Malaria Pf/Pv Plus and NxTekâ„¢ Malaria Pf Plus results when used in its intended environment (NPT setting) by intended users (non laboratory healthcare workers with limited training) using CWBFS as the sample type.*see NPT definition Section 4.2-4.3 of protocol (or below sections on trial operator types and trial envitronment types).
|
Kanungu, Market Cell
Wakiso, Maganjo
Wakiso, Central Ward
|
Uganda |
2021-08-16 |
2024-08-16 |
Section 5.2 of Protocol: Two arms- each kit minimum 90 Pf Positives, 26 Pv Positives, 116 Negatives |
All comers, febrile symptomatic patients of both sexes aged 15 years and above suspected of having malaria and seeking standard medical care at the sites. |
Abbott Diagnostics Korea Inc. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Laura Nsangi Joan
ID: UNCST-2025-R016715
|
ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse
REFNo: HS6040ES
The primary objective is to determine if valganciclovir is safe and efficacious in reducing CMV viraemia amongst hospitalised adults with advanced HIV disease and CMV viraemia.
Secondary objectives are to determine the effect of valganciclovir on mortality, to study its pharmacokinetics and explore the immunological response of patients with CMV viraemia before and after treatment with valganciclovir.
|
Kampala, Mulago
|
Uganda |
2025-07-04 14:08:02 |
2028-07-04 |
150 |
Adults and adolescents (≥ 15 years) diagnosed with advanced HIV disease and CMV viraemia, with a CD4 count ≤ 100 cells/μL and CMV viral load >500 IU/mL. |
Wits Health Consortium |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joseph Matovu KB
ID: UNCST-2020-R014654
|
Enhancing communication on relationship preservation, safer conception, and pre-exposure prophylaxis (PrEP) to promote HIV testing
REFNo: HS3025ES
Conduct a pilot trial of “PrEPing Healthy Families” with intervention sites implementing the novel communication,Conduct formative research to expand a communication strategy focused on relationship preservation and safer conception into a multi-component intervention with broader reach,To leverage the growing availability of PrEP to determine if and how a communication strategy focused on relationship preservation and safer conception can increase testing and entry into treatment (ART) or prevention (PrEP) among couples in Uganda,
|
Mukono, Ntaawo ward
Mityana, Central ward
Butambala, Gombe ward
|
Uganda |
2023-08-25 8:26:15 |
2026-08-25 |
267 |
The proposed study will recruit up to 267 total participants. These participants include project advisory board members (up to 25) clients in assisted partner notification (APN) or antenatal care (ANC) programs (up to 36 for in-depth interviews [IDIs], up to 150 for exit surveys), their partners (up to 36 for IDIs), and ANC/APN providers at the intervention site (up to 20).
Participants will all be aged 18 years and above and all sexes. |
Glenn Wagner |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joseph Matovu KB
ID: UNCST-2020-R014654
|
Reducing hazardous alcohol use and optimizing treatment as prevention among men living with HIV in risk environments
REFNo: HS5558ES
Understand barriers and facilitators in the inner and outer context for implementing the components of Kisoboka within the routine clinical setting to inform future widespread implementation guided by the Exploration, Preparation, Implementation and Sustainment (EPIS) framework and documentation of intervention and implementation costs. ,Assess the impact of the Kisoboka intervention and its components on measures of psychological, physical, and socioeconomic well-being that capture frequent comorbidities of people living with HIV and are associated with achieving successful treatment as prevention,Determine the efficacy of the Kisoboka intervention and its components on alcohol and HIV outcomes among hazardously drinking men living with HIV in Uganda in a 2x2 factorial RCT. ,Assess the efficacy of Kisoboka and its components (BE & MI) to gain insight into Kisoboka’s potential effect, determine if BE and MI interact and examine barriers and facilitators for implementing Kisoboka within routine clinical settings to inform future widespread implementation.,
|
Buikwe, Kawolo
Buikwe, Buikwe Mbiko
Buikwe, Nyenga
Buikwe, Ngogwe
Buikwe, Buikwe Ssi
Buikwe, Makonge
Buikwe, Buikwe Njeru
Nakasongola, Nakasongola Town
Nakasongola, Lwampanga
Nakasongola, Kalungi
Nakasongola, Nabiswera
Nakasongola, Nakayonza
|
Uganda |
2025-02-14 15:19:41 |
2028-02-14 |
820 |
Eligibility is men aged ≥18, living with HIV, residing in a fishing community (on most days/nights), AUDIT-C positive (≥4) indicating potential hazardous alcohol drinking and >6 months since initial ART initiation, last VL was detectable or missing, not planning to move from the area within the next 6 months and have their own mobile phone and can be reached via phone. |
National Institute of Health (NIH) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Juliet Babirye Ndimwibo
ID:
|
TREAT INTERACT: Implementing a user involved education- and health system interactive task-shifting approach for child mental health promotion in Uganda
REFNo: HS3144ES
Based on findings from objectives 1-2, develop implementation advice to guide policymakers in school-based child and adolescent mental health (CAMH) management, integration with the health system, and how to implement and sustain large-scale evidence-informed CAMH interventions to contribute towards achieving universal mental health coverage. ,Develop, implement and evaluate an intersectoral supervision, referral and communication model between the health and education sector.,Implement the adapted module-based TREATment mhGAP school program and investigate effective implementation strategies and client outcomes.,Intervention mapping to adapt the mhGAP-IG to a primary school setting, and implementation mapping to develop implementation strategies with user involvement,The main objective of the TREAT INTERACT study is to adapt, implement and evaluate the impact of an adapted school version of the mhGAP-IG that aims to prevent, identify, refer and treat mental health problems in children and adolescents in Uganda through a user involved task-shifting implementation of the mhGAP-IG among primary school staff. This work is divided into 4 work Packages (WPs); each of the specific objectives below represents a single work package.,
|
Mbale, Primary schools
|
Uganda |
2024-02-02 12:05:35 |
2027-02-02 |
612 teachers |
Teachers and pupils at primary schools |
Norwegian research Council |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joweria Nambooze
ID: UNCST-2019-R001118
|
Effect of consumption of cape gooseberries on blood glucose control among patients with type 2 diabetes mellitus in Kampala, Uganda
REFNo: HS6017ES
To evaluate patient adherence to dietary interventions involving gooseberries,To compare change in glycated hemoglobin (HbA1c) levels among T2DM patients consuming gooseberries regularly as part of their diet with those following a regular diet. ,To assess the effect of regular consumption of gooseberries on fasting blood glucose levels in T2DM patients.,To evaluate the effect of cape gooseberries on blood glucose control among patients with T2DM in Kampala, Uganda.,
|
Kampala, All parishes
|
Uganda |
2025-09-26 18:13:11 |
2028-09-26 |
200 |
The study will include adult patients with T2DM who attend the Saint (St) Francis Nsambya hospital diabetes clinic and the Mulago hospital diabetes clinic in Kampala. Convenience sampling will be used to select patients from these clinics who meet specific study criteria and are readily accessible. The two study sites will be purposively selected due to having established T2DM clinics, high patient volume, diverse population and proper patient records. However, the study participants will be randomly allocated to the study arms. |
Kyambogo University |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joseph Ngonzi
ID: UNCST-2019-R001579
|
Automated visual evaluation and geospatial mapping for cervical cancer screening optimization in sub-Saharan Africa (AVE-Map)
REFNo: HS2069ES
3. To use AVE and geospatial analysis to scale up cervical cancer screening in Uganda ,2. To determine access to cervical cancer screening and referral pathways in Uganda ,1. To validate and expand use of AVE for cervical cancer screening in SSA ,We aim to leverage and develop data science expertise at our sites to first optimize and then combine AVE-based screening by health workers at peripheral health facilities with geospatial-analysis and needs-driven assessment to inform scale-up of cervical cancer screening in Uganda ,
|
,
Mbarara, Kakoba
|
Uganda |
2022-02-28 |
2025-02-28 |
2000 |
Females aged 25 years and above |
NATIONAL INSTITUTE OF HEALTH |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Johanna Blomgren
ID: UNCST-2021-R012309
|
MIDWIZE - Strengthening midwives to implement and sustain quality improvements to optimise maternity care: A longitudinal observational study in Uganda
REFNo: HS1885ES
This PhD project aims to explore how midwives can take the lead in implementing or enhancing QI components within maternal health care in Uganda.
The overall goal of this project is to improve the health of women and newborns. The way to achieve this is through enhancing the quality of care by capacitating midwives.
Sub-study 1 - Co-creating and developing the intervention and the implementation
Specific objectives: To explore multisectoral stakeholders' perspectives and ideas on how to strengthen midwives' capacity to implement QI components.
To explore which QI components the midwives will implement or enhance.
Sub-study 2 - Implementation and evaluating the sustainability of the implementation
Specific objectives:
-To measure the uptake of evidence-based QI components when midwives lead, organise and provide enhanced intra- and postpartum care.
-To measure the long-term sustainability of the midwives' QI projects.
Sub-study 3 – Process evaluation
Specific objective: To evaluate the process of strengthening midwives' capacity to implement QIs in maternal care.
|
Kampala,
|
Sweden |
2022-03-21 |
2025-03-21 |
668 |
Study 1
Midwives at Naguru hospital, women and their relatives, other professionals and managers, multisectoral stakeholders (professional association, education, policymakers)
Study 2
Pregnant women above 18 years in the uptake area. However, dependin |
Karolinska Institutet |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
.png)
|
Jolly Kamugisha G.K.
ID: UNCST-2023-R005715
|
Performance and Factors Affecting the Implementation of the Integrated Management of Acute Malnutrition Programme: A Study of Kampala, Mukono, Wakiso and Kayunga Districts
REFNo: HS6084ES
5. To document the lessons learnt and best practices during implementation of the IMAM program in the four target districts during the calendar year 2022 and 2023.,4. To establish factors that affect the utilization of IMAM services in the four target districts.,3. To determine factors influencing treatment outcomes of children with wasting in the four target districts.,2. To determine the performances of the integrated management of acute malnutrition program in the four target districts during the calendar year 2022 and 2023.,1. To identify the communities contributing to a high burden of childhood wasting caseload in health facilities in four target districts (Kampala, Mukono, Wakiso and Kayunga),The overall objective of this study is to assess the nutrition service delivery and factors influencing utilization of the IMAM programme in Kampala, Mukono, Wakiso and Kayunga districts,
|
Kampala,
Mukono,
Wakiso,
Kayunga,
|
Uganda |
2025-06-20 8:41:29 |
2028-06-20 |
Sample size varies by objective as follows: Objective 1: 1440 records; Objectives 3-5: 5 key informants ()KIIs) at policy level; 8 KIIs - district and facility administrators; 7 KIIs for health workers at facility level. |
1) Children aged < 5years with acute malnutrition - both boys and girls (Records review)
2) Caregivers of children treated acute malnutrition (both females and males aged 18+years)
3) Village Health Teams (both males and females adults aged 18+ years)
4) Health workers caring for children with acute malnutrition (Male and females aged 18+ years; District and health facility administrators (male and female aged 18years
5) Policy level stakeholders, both male and female aged 18+ years)
|
UNICEF |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jonathan Izudi
ID: UNCST-2019-R000469
|
Effectiveness of Multi-Month Dispensing of Anti-Tuberculosis Drugs (MULTI-DAT) Versus Standard of Care on Treatment Success Rate Among People with Drug Susceptible Tuberculosis in Rural Eastern Uganda
REFNo: HS3953ES
To evaluate the effectiveness of MULTI-DAT on cure and treatment success rates at 6 months of treatment compared to the standard of care (SOC) using an open-label, individually randomized controlled trial or RCT (Aim 2). ,To explore stakeholder perceptions regarding the relevance and appropriateness of MULTI-DAT, including the delivery of MULTI-DAT among people with drug-susceptible PTB aged ≥15 years using a qualitative study (Aim 1).,Overall, the MORAD study will focus on the practicability and effectiveness of MULTI-DAT among people with drug-susceptible pulmonary TB (PTB) aged ≥15 years on the standard 6-month anti-TB treatment regimen in eastern Uganda,
|
Soroti, Soroti
Kumi, Kumi
Serere, Serere
Not Applicable (N/A), Soroti
|
Uganda |
2024-03-27 18:52:57 |
2027-03-27 |
66 stakeholders (Aim 1); 260 participants in a 1:1 ratio (Aim 2) |
Aim 1: i) TB focal persons with ≥1 year of work experience; other stakeholders with ≥3 years of work experience in TB; ii) People with TB on treatment for ≥4 months including the respective treatment supporters.
Aim 2: People with drug-susceptible PTB ≥15 years. |
UC Berkeley |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
Jonathan Izudi
ID: UNCST-2019-R000469
|
Integrating Tuberculosis Treatment into Community Pharmacies to improve TB/HIV outcomes in Uganda: the Community Pharmacy Tuberculosis Treatment (COPHAT) study
REFNo: HS4397ES
To evaluate the implementation and preliminary effectiveness of integrating TB treatment into community pharmacies among people with TB/HIV.,To adapt a person-centered strategy for integrating TB treatment into community pharmacies using a human-centered design methodology.,To explore the barriers and facilitators to integrating TB treatment into community pharmacies among people with TB/HIV.,The main objective of this Community Pharmacy Tuberculosis Treatment (COPHAT) study is to develop and pilot an implementation strategy focused on integrating TB treatment into community pharmacies among people with TB/HIV in Kampala, Uganda. ,
|
Kampala, Kisugu
Kampala, Kisenyi
Kampala, Kaawala
Kampala, Kitebi
Kampala, Komamboga
Kampala, Kiswa
|
Uganda |
2024-06-21 17:46:35 |
2027-06-21 |
126 |
People with TB/HIV, ART focal persons, TB focal persons, MoH officials, and Community Pharmacy health workers, aged 18 years and over, irrespective of tribe. |
National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
JOSELYN RWEBEMBERA
ID: UNCST-2021-R013915
|
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A non-inferiority randomized trial. (GOALIE)
REFNo: HS2659ES
Primary Objective:
To compare the proportion of children aged 5-17 years with latent RHD receiving oral penicillin prophylaxis who progress to worse valvular disease at 2-years compared to children who receive IM penicillin prophylaxis.
|
Lira, Adyel
|
Uganda |
2023-03-24 2:23:26 |
2026-03-24 |
1004 |
Age group = 5-17
Sex not specified.
Tribe not specified. |
National Institute of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
JOSELYN RWEBEMBERA
ID: UNCST-2021-R013915
|
A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop
REFNo: HS6744ES
To explore if risk of progression differs between children who initially received 2 years of oral SAP as compared to 2 years of intramuscular SAP during the GOALIE trial. ,To determine in children with previously diagnosed mild RHD and echocardiographic stabilization after receiving SAP for at least 2 years, if stopping secondary antibiotic prophylaxis (SAP) is non-inferior to continuing SAP in preventing progression over the next 2 years. ,To determine in children with previously diagnosed mild RHD and echocardiographic normalization after receiving SAP for at least 2 years, if stopping SAP is non-inferior to continuing SAP for preventing progression over the next 2 years. ,To determine in children with previously diagnosed mild RHD and echocardiographic normalization or echocardiographic stability after receiving SAP for at least 2 years, if stopping SAP is non-inferior to continuing SAP for preventing progression by 4 years (2 years after SAP discontinuation). ,
|
|
Uganda |
2025-12-18 18:47:07 |
2028-12-18 |
992 |
Children and adolescents will be eligible for study participation if they (1) participated in the GOALIE Trial, (2) are found to have echocardiographic normalization or stable mild RHD at study completion, (3) are between the ages of 5-20 years at the time of enrollment. |
Thrasher Research Fund & Open Philanthropy |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joseph Lutaakome
ID: UNCST-2020-R008323
|
An International Multicenter, Randomized, Double-Blind, PlaceboControlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
REFNo: HS1715ES
Primary Objective
Primary objective: Among outpatients with recently diagnosed SARS-CoV-2 infection to compare the safety and efficacy of a single infusion of hIVIG (pooled for the 2 hIVIG
products) versus placebo, each given with SOC, on clinical status after seven days. Two hypotheses will be tested to address this primary objective, which compares the primary endpoint among two study populations: 1) participants where neutralizing MAb was not specified as part of SOC treatment (stratum 1, see Section 6.1 Overall Study Design); and 2) all randomized participants (stratum 1 and stratum 2 combined). hIVIG will be considered superior to placebo if either of the two hypotheses are rejected.
Secondary Objectives and Endpoints
Secondary objectives, including subgroup analyses and safety outcomes, will be addressed for all randomized participants and for those in stratum 1 and 2 separately.
Secondary Endpoints
The clinical status as classified on the ordinal outcome scale will be assessed with a number of additional analyses comparing hIVIG (pooled for the 2 hIVIG products) with placebo, among the overall study population as well as for the key subgroup of those not receiving anti-SARS-CoV-2 monoclonal antibodies as part of SOC (stratum 1), including:
1. All-cause hospitalization or death through 28 days.
2. All-cause mortality through 28 days.
3. Significant disease progression through 28 days, using a time to event analysis with outcome defined by fulfilling criteria for category 4 or 5 on the ordinal scale.
4. Distribution of ordinal scale outcome at Day 4, 14, and 28.
5. The proportion of participants with any disease progression at Day 7, using a sliding dichotomous scale progression defined by a categorization on the ordinal scale that is worse than the status at entry
|
|
Uganda |
2021-10-04 |
2024-10-04 |
A sample size for this phase 3 trial of 820 participants is planned, which would consist of at least 656 participants in stratum 1. |
In order to be eligible to participate in this study, a patient must meet all of the following inclusion criteria prior to randomization:
i. Clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an
ii. immunosuppressed condition.
|
The study is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, through their contract organization Leidos. There is a subcontract between the University of Minnesota (the Sponsor) and the MRC CTU at UCL. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joseph Lutaakome
ID: UNCST-2020-R008323
|
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE)
REFNo: HS2703ES
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) is a master protocol being conducted in many countries around the world, and funded by the National Institutes of Health, USA. STRIVE will evaluate the safety and effectiveness of unlicensed and licensed treatments and different combinations of treatments, to improve the health outcomes of adults
hospitalised with acute respiratory infections, like COVID-19 or influenza.
|
Kampala, Kampala
Masaka, Masaka
Gulu, Gulu
Lira, Lira
|
Uganda |
2023-08-08 12:39:21 |
2026-08-08 |
1,500 |
The participant population are non-pregnant or breast-feeding adults aged ≥ 18 years; with confirmed COVID-19 for <14 days, and requiring inpatient hospital acute medical care and with evidence of a COVID-19 lower respiratory tract infection. |
National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joshua Muhumuza
ID:
|
Effect of chewing gum on duration of postoperative ileus following laparotomy for gastroduodenal perforations; a multi centre study.
REFNo: HS1665ES
i. To compare the time taken for post-operative ileus to resolve in the two groups.
ii. To compare the duration of hospital stay in the two groups.
iii. To determine other factors associated with the duration of post-operative ileus in the study population.
|
Kabarole, Central Division
Bushenyi, Central Division
Hoima, Central Division
|
Uganda |
2022-05-30 17:10:09 |
2025-05-30 |
52 participants |
All adult patients 18 years and above, male and female admitted to the surgical wards of study centre hospitals irrespective of tribe with gastric or duodenal perforations during the study period at will be the study population |
self sponsored |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Joy Gumikiriza- Onoria Louise
ID:
|
Development of a Caregiver Centered Psychotherapy (CCPT) in addressing patient care for older persons with Alzheimer’s Disease and Related Dementias (ADRD) in Uganda.
REFNo: HS2909ES
1. To explore ways in which older people in the community of Wakiso district conceptualize ADRD and what informs their opinions. 2. To assess caregiver distress, non-professional techniques of patient care, quality of life and the associated factors among family caregivers of persons with ADRD in Wakiso district.To adapt and pre-test the WHO-iSupport for family caregivers of persons with ADRD in Wakiso, Uganda4. To determine the effectiveness of A-iSupport in the alleviation of distress among family caregivers of persons with ADRD in Wakiso, Uganda
|
Wakiso, Busukuma
Wakiso, Nansana
|
Uganda |
2023-07-14 9:40:03 |
2026-07-14 |
180 |
All residents of Wakiso district aged 60 years and older, includidng caregivers of persons with ADRD |
BRAIN health |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
JULIET MWANGA-AMUMPAIRE
ID: UNCST-2022-R009420
|
An open-label, multicentre, randomized, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19
REFNo: HS1789ES
Primary objective: to compare the efficacy of alternative treatment strategies versus control on the risk of progression to severe respiratory disease
The secondary objectives are:
 To compare the safety of each study arm to control, up to Day 21 of follow-up
 To compare the rate of hospitalizations due to COVID-19 in each study arm versus control
 To compare the time to hospitalization due to COVID-19 in each study arm versus control
 To compare the rate of hospitalizations for other reason than Covid-19 in each study arm versus control
 To compare the disease-free rate in each study arm versus control
 To compare the death rate in each study arm versus control
 To compare time to worsening of SpO2 < 93in each study arm versus control
 To compare the capacity to prevent severe progression between study arms
 To identify risk factors for severe progression
 To assess efficacy in sub-groups of patients e.g. with pre-existing conditions/co-morbidities, by age group, sex, BMI, timeframe between onset of symptoms and randomization.
|
Mbarara, Mbarara Medical Cell
|
Uganda |
2021-12-07 |
2024-12-07 |
175 |
1. Male or female patients,
2. Adult’s  18 years of age at the time of screening. Children > 12 years of age may be included if recommended by the DSMB after the first analysis.
3. COVID-19 confirmed by molecular biology or validated antigenic test |
Drugs for Neglected Diseases Initiative (DNDi) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
